We are looking for a computational postdoc with experience in large-scale analysis and interpretation of human genome and epigenome data and an interest in personalized cancer therapy. Our group combines computational and experimental methods for understanding epigenome regulation in cancer, stem cells and immunity, and we operate the leading technology platform for biomedical sequencing in Austria.
The Lab [http://www.medical-epigenomics.org/]
The lab combines large-scale analysis of the epigenome with stem cell biology and computational modeling, in order to better understand and treat leukemia and other cancers. We work closely with biologists and medical researchers at the Medical University of Vienna, aiming to advance personalized medicine through epigenome sequencing and bioinformatic innovation. Specific research interests include (but are not limited to):
• Epigenomics. The lab is part of the BLUEPRINT project aimed at establishing, analyzing and interpreting comprehensive epigenome maps of >100 cell types of the blood and immune system.
• Bioinformatics. We develop bioinformatic methods and infrastructure for analyzing DNA methylation data in the context of epigenome-wide association studies.
• Diagnostics. Using large-scale DNA methylation mapping, bioinformatic prioritization and functional characterization, we strive to develop clinically relevant biomarkers for informing cancer therapy.
The Principal Investigator [http://christoph-bock.org/]
Christoph Bock received his training in computer science and business science from the Universities of Mannheim and Heidelberg (Germany). He obtained a PhD in bioinformatics from the Max Planck Institute for Informatics, for which he was awarded an Otto Hahn Medal by the Max Planck Society. Christoph did his postdoc in epigenome research at the Broad Institute of MIT and Harvard, contributing to the Roadmap Epigenomics Project. In parallel, Christoph led a research group on computational epige-netics at the Max Planck Institute for Informatics. His recent publications include papers in Cell, Molecular Cell, Nature Biotechnology, Nature Methods, Nature Reviews Cancer, Nature Reviews Genetics, Genome Research, Genome Biology, PLoS Computational Biology, Bioinformatics, NEJM and Science (http://scholar.google.com/citations?user=9qSsTcIAAAAJ). Christoph also leads a next generation sequencing platform in Vienna (http://biomedical-sequencing.at), he is a guest professor at the Medical University of Vienna and a work package leader in the European epigenome mapping project (http://blueprint-epigenome.eu).
We currently have postdoc positions available in the context of the following European initiatives:
• The European BLUEPRINT project focusing on large-scale dissection of epigenome regulation in blood & leukemia
• Two new European consortia focusing on epigenetic mechanisms as causes and biomarkers of breast/ovarian cancer
Furthermore, we are open to exciting new project ideas in the fields of genomics & epigenomics, bioinformatics and cancer.
We are looking for highly motivated and academically outstanding candidates who want to pursue a scientific career in the emerging field of medical epigenomics. An ideal candidate would have a background in molecular biology or a related discipline (human genetics, genomics, molecular medicine, chemical biology, etc.) or a computational discipline (bioinformatics, physics, engineering, etc.) and a strong interest in working together with collaborators in the entire spectrum of epigenetics, bioinformatics and personalized medicine. Scientists with a medical degree and an interest in biomedical research are encouraged to apply. Prior work experience in a world-class research institution and publications in relevant international journals are a requirement.
Please submit cover letter, curriculum vitae, academic transcripts and contact details of three referees to email@example.com. Please indicate the reference code Postdoc Bock Lab in subject line. Deadline for applications: 30 April 2014 (the start date is very flexible between essentially immediately and up to 1-2 years into the future).